MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2026)

MoonLake Immunotherapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $35000.0 for Q1 2025.

• In Q1 2025, Capital Expenditures changed N/A year-over-year to $35000.0; the TTM figure through Dec 2025 stood at $35000.0 (down 93.27% YoY), while the FY2025 annual figure was $35000.0, down 93.27% from the prior year.
• Capital Expenditures for Q1 2025 stood at $35000.0, down from $176000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $344000.0 in Q3 2024, with the low at -$2.0 in Q2 2022.
• The 4-year median for Capital Expenditures is $32376.0 (2021), against an average of $81433.9.
• Peak annual rise in Capital Expenditures reached 100.0% in 2022, while the deepest fall reached 100.0% in 2022.
• MoonLake Immunotherapeutics' Capital Expenditures stood at $50710.0 in 2021, then slumped by 100.0% to $1.0 in 2022, then surged by 17599900.0% to $176000.0 in 2024, then plunged by 80.11% to $35000.0 in 2025.
• Business Quant data shows MLTX's Capital Expenditures at $35000.0 in Q1 2025, $176000.0 in Q4 2024, and $344000.0 in Q3 2024.